ProACT Post-Approval Study
Status: | Recruiting |
---|---|
Conditions: | Urology, Urology |
Therapuetic Areas: | Nephrology / Urology |
Healthy: | No |
Age Range: | 50 - Any |
Updated: | 2/23/2019 |
Start Date: | February 19, 2019 |
End Date: | December 1, 2027 |
Contact: | Timothy C Plouffe |
Email: | tplouffe@uromedica-inc.com |
Phone: | 7636949880 |
Post Approval Study of the ProACTâ„¢ Adjustable Continence Therapy for Men
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study
designed to evaluate the long-term incidence of urethral stricture and device erosion after
ProACT implantation. In addition, the study will evaluate whether treatment with ProACT
affects clinical outcomes after subsequent SUI therapies.
designed to evaluate the long-term incidence of urethral stricture and device erosion after
ProACT implantation. In addition, the study will evaluate whether treatment with ProACT
affects clinical outcomes after subsequent SUI therapies.
Inclusion Criteria:
1. Subject is a male of at least 50 years of age.
2. Subject demonstrates stress urinary incontinence.
3. Subject has undergone a radical prostatectomy, transurethral resection of the
prostate, or other prostate surgery.
4. Subject is willing and able to undergo surgical implantation of ProACT devices.
5. Subject is willing and able to comply with study-required
follow-up activities, including annual telephonic follow -up interviews, for a period
of 5 years from their date of initial implantation. This includes compliance even
after possible explant of ProACT devices and/or possible implantation of subsequent
therapies.
6. Subject is willing and able to sign the approved informed consent.
7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad
weight increase demonstrated in two 24-hour pad weight tests).
8. Subject has a negative urine culture.
9. Subject has no known urogenital malignancy, other than previously treated prostate
cancer.
10. Subject meets ONE of the following criteria:
1. Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
2. Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater
than or equal to 25% of total PSA;
11. Physician determines subject to be a suitable surgical candidate.
Exclusion Criteria:
1. Subject has an existing urethral stricture, a history of any urethral strictures, or
has ever had a urethrotomy.
2. Subject has undergone prostate surgery or any anti-incontinence surgery within the
last 12 months.
3. Subject has an artificial urinary sphincter or any components of a previously
implanted artificial urinary sphincter in vivo.
4. Subject has undergone radiation therapy in the prostatic area within the last 12
months.
5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
6. Subject has an atonic bladder.
7. Subject had, presently has, or is suspected of having bladder cancer.
8. Subject has untreated or unsuccessfully treated bladder stones.
9. Subject has detrusor sphincter dyssynergia.
10. Subject has known hemophilia or a bleeding disorder.
11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or
respiratory arrest).
12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as
indicated by an A1c test result of = 6.5%.
We found this trial at
2
sites
500 S State St
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Bahaa Malaeb, MD
Phone: 734-647-3096
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Lindsey Hartsell, MD
Phone: 404-778-4729
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials